Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7372943 | 0.94 | MAOB (0.89) | MAOBARLMNACYP1A2PTGS1 | |
| SCHEMBL28961976 | 0.94 | MAOB (0.89) | MAOBARLMNACYP1A2PTGS1 | |
| SCHEMBL7311874 | 0.93 | MAOB (0.86) | MAOBARLMNACYP1A2PTGS1 | |
| SCHEMBL8618909 | 0.92 | MAOB (0.85) | MAOBARLMNACYP1A2PTGS1 | |
| SCHEMBL30354424 | 0.90 | MAOB (0.81) | MAOBARLMNACYP1A2PTGS1 | |
| SCHEMBL29741480 | 0.90 | MAOB (0.81) | MAOBARRAB9AMAOACYP19A1 | |
| SCHEMBL18664184 | 0.90 | MAOB (0.81) | MAOBARRAB9AMAOACYP19A1 | |
| SCHEMBL20240306 | 0.89 | MAOB (0.80) | MAOBARRAB9ABCHECYP19A1 | |
| SCHEMBL1249162 | 0.89 | MAOB (0.80) | MAOBARRAB9ABCHECYP19A1 | |
| SCHEMBL8806782 | 0.88 | MAOB (0.78) | MAOBARRAB9AMAOABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113861069-B | Preparation method of nitrile compound | 陕西国际商贸学院 | 2023-06-16 | — | — | CN | claimed |
| EP-1055658-B1 | Process for cis-1- 2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl pyrrolidine | PFIZER PROD INC (US) | 2003-03-12 | — | — | EP | claimed |
| US-20020042524-A1 | Process for cis-1{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy] ethyl}pyrrolidine | CHIU CHARLES K F (US) | 2002-04-11 | — | — | US | claimed |
| US-6323345-B1 | BROMINATING 2-BROMO-5-METHOXY-TOLUENE TO PROVIDE 1-BROMO-2-BROMOMETHYL-4-METHOXYBENZENE; DECARBOXYLATION, REACTING WITH ETHYLENE GLYCOL; REACTING WITH N-BUTYL LITHIUM AND 4-BENZYLOXY BENZONITRILE; HYDROLYSIS, HYDROGENATION | PFIZER INC. | 2001-11-27 | — | — | US | claimed |
| CN-1280128-A | Process for the preparation of cis-1- { 2- [ 4- (6-methoxy-2-phenyl-1, 2,3, 4-tetrahydronaphthalen-1-yl) phenoxy ] ethyl } pyrrolidine | PFIZER PRODUCT CO (US) | 2001-01-17 | — | — | CN | claimed |
| EP-1055658-A2 | Process for cis-1- 2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl pyrrolidine | Pfizer Products Inc. (US) | 2000-11-29 | — | — | EP | claimed |
| JP-1316367-A | — | — | None | — | — | JP | disclosed |
| US-20250388542-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | AURANSA INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4559918-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3673906-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-115515685-B | EIF4E inhibitors and uses thereof | 皮克医疗公司 | 2025-04-08 | — | — | CN | disclosed |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| US-12157731-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2024-12-03 | — | — | US | disclosed |
| US-4973425-A | ELECTROOPTICS | DAISO CO., LTD. (JP) | 1990-11-27 | — | — | US | disclosed |
| US-4909957-A | Containing lactone ring structure | DAISO CO., LTD. (JP) | 1990-03-20 | — | — | US | disclosed |
| EP-0355830-A2 | Liquid crystal composition and use thereof | DAISO CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
| JP-H01316367-A | LIQUID CRYSTAL SUBSTANCE HAVING HETEROCYCLIC SKELETON | SHOWA SHELL SEKIYU KK | 1989-12-21 | — | — | JP | disclosed |
| EP-0328026-A1 | Substituted pyrroles | F. HOFFMANN-LA ROCHE AG (CH) | 1989-08-16 | — | — | EP | disclosed |
| EP-0306919-A2 | Liquid crystalline compounds and process for production thereof | DAISO CO., LTD. (JP) | 1989-03-15 | — | — | EP | disclosed |
| US-4098816-A | HYPOGLYCEMIC AGENTS AND ANTILIPEMIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388542-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | MALT1, SLC38A7, SLC7A1 | MAOB 4499/4885AR 546/4885LMNA 3402/4885 |
| US-20020042524-A1 | Process for cis-1{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy] ethyl}pyrrolidine | P4HA1, PAH, DNM1 | MAOB 3174/4885AR 1299/4885LMNA 1208/4885 |
| US-12157731-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | MAOB 4402/4885AR 3889/4885LMNA 2647/4885 |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | MAOB 693/4885AR 3951/4885LMNA 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.